FCFátima Ceia

Fátima Ceia

*This is an algorithmically generated author record based on publicly available information.

Fátima Ceia has a total of 46 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 1 February 2011
      • Vol. 30  (2) , 171-80

    Atrial fibrillation and thromboembolic risk: what is the extent of adherence to guidelines in clinical practice?

    by Hélder Dores, Rosa Cardiga, Ricardo Ferreira, Inês Araújo, Filipa Gândara, Ana Abreu, Filipa Marques, Ana Leitão, Cândida Fonseca, Fátima Ceia

    Atrial fibrillation (AF) is the most common cardiac rhythm disorder in clinical practice, with a growing prevalence in recent decades. Through the use of thromboembolic risk scores it is possible to adjust thromboprophylaxis to individual risk. The aim of this study was to evaluate the conformity of antithrombotic therapy prescribed at hospital discharge with the guidelines in patients with AF and its influence on long-term morbidity and mortality. We performed a retrospective analysis, based on medical records and phone interview, of consecutive patients admitted to an internal medicine department over a one-year period with a diagnosis of AF or atrial flutter--ICD-9-CM 427.31/32. We determined individual thromboembolic risk in accordance with the ACC/AHA/ESC risk categories, and assessed conformity of antithrombotic therapy with the guidelines. Independent predictors of long-term (378 +/- 241 days) mortality and mortality or readmission were identified by multivariate analysis. The study population consisted of 174 patients with a diagnosis of AF, 59.8% (104) female, mean age 77 +/- 10 years. Hypertension (65.7%) and heart failure (61.3%) were the most prevalent comorbidities. Most patients (82.7%) were stratified as high thromboembolic risk and the remainder as moderate risk. The antithrombotic therapy prescribed at hospital discharge was documented in 155 patients, 126 (81.3%) with high thromboembolic risk. Of the latter group of patients, oral anticoagulation (OAC) was prescribed in 65 (51.6%) and proposed but contraindicated in 24 (19.0%). In patients with moderate thromboembolic risk, therapeutic options were divided between OAC (69.0%), antiplatelet therapy (17.2%) and no thromboprophylaxis (13.8%). Overall there was discordance between the therapy instituted and the guidelines in 25.8% of patients. Age 85 years or over was the only independent predictor of death (HR 1.92; 95% CI 0.94-3.91), while OAC (HR 0.43; 95% CI 0.27-0.70) and male gender (HR 0.58; 95% CI 0.36-0.94) were independent protective factors against death or hospital readmission. In this study, patients admitted with AF were mainly elderly, women and with high thromboembolic risk. The prescription rate of OAC in patients at high risk was lower than recommended in the guidelines, which were not followed in a quarter of patients. The main therapeutic option in cases of moderate risk was OAC. OAC use was the only modifiable factor able to improve prognosis of patients with AF, and it is thus crucial to ensure adherence to the guidelines in daily clinical practice.


    • 30 July 2010
      • Vol. 23  (4) , 625-30

    [Clinical predictors of infectious pulmonary tuberculosis.].

    by Joana Silvestre, Ana Leitão, Cândida Fonseca, Dolores Alberca, Filipa Marques, Ana Abreu, Inês Araújo, Isabel João, Ana Aleixo, Fátima Ceia

    The immediate identification of infectious tuberculosis and implementation of effective isolation measures, are a priority of the national policies for disease control. To identify clinical predictor's factors related with sputum smear-positive, in patients with pulmonary tuberculosis diagnosis. This was a retrospective study involving 289 patients admitted consecutively with the diagnosis of tuberculosis (ICD-9-CM: 010-018) through the emergency department of a Central Hospital. The study was conducted from January 1999 to December 2005. 216 patients (74.7%) were identified with pulmonary tuberculosis: mean age 40.3 (SD 16.1); 77.8% males. Of these 179 (82%) were smear-positive and 157 (54.5%) had human immunodeficiency virus (HIV) co-infection. Of the 37 patients with sputum smearnegative 18 (48.6%) had culture positive. The clinical factors that were better related with sputum smear-positive were: cough with sputum (p = 0.031) and classic chest radiograph patterns, parenchymal consolidation (p < 0.001) and cavitation (p = 0.002). HIV co-infection wasn't associated with a higher risk of infectious tuberculosis. Respiratory symptoms and classic patterns on chest radiograph, were clinical factors better related with a higher probability of sputum smear-positive. In these patients it is a good clinical practice to propose immediate isolation measures even before the results of sputum smear.

  • P0826 HEART FAILURE AND NONVALVULAR ATRIAL FIBRILLATION: AN UNEQUIVOCAL RELATIONSHIP

    by Helder Dores, Ricardo Ferreira, Rosa Cardiga, Filipa Gândara, Filipa Marques, Inês Araújo, Ana Leitão, Cândida Fonseca, Fátima Ceia

  • O0004 STROKE PREVENTION ON NONVALVULAR ATRIAL FIBRILLATION: WHICH RISK STRATIFICATION SCORE DO WE CHOOSE?

    by Helder Dores, Rosa Cardiga, Ricardo Ferreira, Filipa Marques, Filipa Gândara, Inês Araújo, Cândida Fonseca, Ana Leitão, Fátima Ceia

    • 1 September 2008
      • Vol. 27  (9) , 1029-42

    Portuguese study of familial dilated cardiomyopathy: the FATIMA study.

    by Elisabete Martins, José Silva-Cardoso, Manuel Bicho, Mafalda Bourbon, Fátima Ceia, M José Rebocho, Brenda Moura, Cândida Fonseca, Maria José Correia, Dulce Brito, et al.

    Dilated cardiomyopathy (DCM) is a myocardial disease, characterized by ventricular dilatation and impaired systolic function, that in more than 30% of cases has a familial or genetic origin. Given its age-dependent penetrance, DCM frequently manifests in adults by signs or symptoms of heart failure, arrhythmias or sudden death. The predominant mode of inheritance is autosomal dominant, and in these cases mutations are identified in genes coding for cytoskeletal, sarcomeric or nuclear envelope proteins. To date, most studies aimed at molecular diagnosis of DCM have been in selected families, or in larger groups of patients, but screening for mutations in a limited number of genes. Consequently, the epidemiology of mutations in familial DCM remains unknown. There is thus a need for multicenter studies, involving screening for a wide range of mutations in several families and in cases of idiopathic DCM. The present article describes the methodology of a multicenter study, aimed at clinical and molecular characterization of familial DCM patients in the Portuguese population.


    • 1 November 2007
      • Vol. 26  (11) , 1111-28

    Translating guidelines into clinical practice: benefits of an acute heart failure unit .

    by Candida Fonseca, Fatima Ceia, Pedro Moraes Sarmento, Filipa Marques, Ricardo Covas, Ana Aleixo

    Heart failure (HF) is a very prevalent condition, with high mortality, morbidity and costs, despite the development of effective drug therapy. Many patients still do not have access to appropriate treatment. Heart failure clinics have shown success in improving delivery of appropriate HF management, helping to reduce morbidity and mortality and costs. To compare the quality of diagnosis and drug therapy at discharge in an unselected population of patients admitted to a medical ward of an urban central teaching hospital before and after the creation of a heart failure unit (HFU) and to evaluate its impact on long-term mortality and morbidity from all causes and from HF. We compared a population of 153 patients, aged 75 +/- 12.8 years, 50.3% male, with a diagnosis of HF according to the guidelines of the European Society of Cardiology, NYHA classes II-IV (74% III or IV), admitted consecutively to a medical ward (MW) before the creation of an HFU (Group 1), with a population of 82 patients, aged 73 +/- 12.4 years, 62.2% male, admitted consecutively to the HFU for acute decompensated HF (Group 2). The prescription of diuretics, spironolactone, angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, angiotensin receptor antagonists (ARAs) and warfarin in the two groups at discharge was analyzed. The endpoints of the study were: in-hospital mortality (IM), mortality and hospitalization due to all causes (P1), mortality and hospitalization due to HF (P2), all-cause mortality (P3), and mortality due to HF (P4). The follow-up duration was 18 months. The two populations were not statistically different in gender, age or type of HF. HF diagnosis was correct in 67.7% of cases in Group 1, vs. 86% in Group 2. The increase in the prescription of beta-blockers in Group 2 compared with Group 1 was highly significant (4.9% vs. 36.0%, p = 0.000 in all-cause HF patients and 28.9% vs. 56.8%, p = 0.000, in HF due to systolic dysfunction), as was that of warfarin (16.7% vs. 32.6%, p = 0.003 in all-cause HF and 17.6% vs. 44.4%, p = 0.001, in HF due to systolic dysfunction). IM in the MW vs. HFU was 7.7% vs. 8.5% (p = 0.42). The probabilities for the different end-points in MW/HFU at 6, 12 and 18 months were: P1: 55/35% (p = 0.013), 68/46% (p = 0.0005) and 73/51% (p = 0.0004); P2: 26/19% (p = 0.1), 34/20% (p = 0.008) and 39/23% (p = 0.004); P3: 25.5/21% (p = 0.22), 31/30% (p = 0.44) and 38/35% (p = 0.32); P4: 16/19% (p = 0.28), 23/20% (p = 0.3) and 27/33% (p = 0.25). These results are in agreement with reported morbidity and mortality from the syndrome after hospitalization. There is a tendency for better outcome in all the studied endpoints among the population treated in the HFU, despite greater severity of the disease, compared to those treated in the MW. A statistically significant improvement was found in the composite endpoints of mortality and hospitalization from all causes and due to HF, at 12 and 18 months. The results of the study indicate that the HFU had a better performance in reducing morbidity than mortality compared to the MW. As hospitalization accounts for 60% of HF costs, HFUs are expected to be cost effective.


    • 1 September 2007
      • Vol. 26  (9) , 857-66

    Post-percutaneous coronary angioplasty atheroembolization--a feared iatrogenic complication.

    by Sílvio Leal, Cândida Fonseca, Pedro Sarmento, Filipa Marques, Dulce Carvalho, M Luísa Carneiro De Moura, Fátima Ceia, Ana Aleixo

    Atheroembolic disease is a rarely recognized clinical entity. The growing use of antiplatelet and thrombolytic therapy and of invasive cardiovascular procedures in acute coronary syndromes has nevertheless transformed this feared iatrogenic complication into an increasingly frequent diagnosis. The authors review this entity through the case of a 71-year-old man who, fifteen days after undergoing thrombolysis for acute myocardial infarction with ST-segment elevation, followed by elective percutaneous coronary revascularization under triple antiplatelet therapy, came to the emergency department with a clinical setting of mental confusion, gastrointestinal bleeding, oliguria and cutaneous eruptions on the lower limbs; laboratory tests revealed severe azotemia and hyperkalemia. With a diagnostic hypothesis of systemic atheroembolization, a cutaneous lesion biopsy was performed, which confirmed the diagnosis. Supportive treatment led to neurological and cutaneous recovery, but the patient developed chronic renal failure. The pathophysiology, forms of presentation, treatment and prognosis of atheroembolic disease are discussed, highlighting the importance of a high degree of clinical suspicion for diagnosis.

    • 1 February 2005
      • Vol. 24  (2) , 173-89

    Epidemiology of heart failure in primary care in Madeira: the EPICA-RAM study.

    by Fátima Ceia, Cândida Fonseca, Isabel Azevedo, Teresa Mota, Humberto Morais, Fernando Matias, Catarina Costa, António Gouveia-Oliveira, Representação Dos Investigadores Do Epica-Ram

    Chronic heart failure (CHF) is a serious public health problem all over the world. CHF has a high prevalence, affecting mainly the elderly, and causes severe disability and social and economic costs. To estimate the prevalence of chronic heart failure in the Autonomous Region of Madeira in 2001. This was a community-based epidemiological survey involving subjects attending primary care centers selected by a combined two-stage sampling and stratifying procedure. General practitioners (GPs) randomly selected in proportion to the population of each municipality evaluated subjects aged over 25 years attending primary care centers, recruited consecutively and stratified by age. CHF cases were identified according to the Guidelines of the European Society of Cardiology for CHF diagnosis. Six hundred and eighty-six eligible subjects were evaluated by 30 GPs; 60 patients with CHF were identified. The overall prevalence and 95 % CI of CHF in Madeira was 4.69 % (2.91 % to 6.46 %), 3.53 % in males (0.81 % to 6.26 %), and 5.58 % in females (3.37 % to 7.79 %). CHF prevalence increases with age: 1.24 % (0.00 % to 2.96 %) in the 25 to 49-year-old group, 6.17% (1.31 to 11.03 %) in those aged 50 to 59 years, 7.62 % (0.75 to 14.49 %) in those aged 60 to 69 years, 13.32 % (7.99 % to 14.49 %) in the 70 to 79-year-old group, and 14.34 % in the group over 80 years old (7.59 % to 21.09 %). The prevalence of CHF due to systolic dysfunction was 0.76 % and 2.74 % with normal systolic function. The overall prevalence of CHF in Madeira was similar to that of mainland Portugal, and slightly higher than that of other European studies. Overall CHF prevalence increases sharply with age. The prevalence of CHF with preserved systolic ventricular function was similar to that reported by other recent European studies. The prevalence of CHF due to systolic dysfunction was much lower. The differences found may correspond to differences in methodology rather than actual differences in the population. CHF with left ventricular systolic dysfunction seems to be rare in primary care in Madeira. This may be related to the different public health organization in Madeira, and deserves further evaluation.

    • 14 October 2004
      • Vol. 23, 979-91

    Comparative value of BNP and NT-proBNP in diagnosis of heart failure.

    by Candida Fonseca, Pedro M Sarmento, Ana Minez, Elsa Gonçalves, Ricardo Covas, Ana Ramos Dias, Maria Julieta Esperança Pina, Fátima Ceia

    Heart failure (HF) remains a major diagnostic challenge. Brain natriuretic peptide (BNP) and the N-terminal portion of proBNP (NT-proBNP) have emerged as excellent diagnostic biohumoral indicators in cardiac disease. It is not clear which of the two is superior as a diagnostic marker in HF. To compare the ability of BNP and NT-proBNP to distinguish subjects with HF from healthy volunteers, as well as to differentiate between HF with left ventricular (LV) systolic dysfunction (SD) and HF with preserved systolic function (PSF). We measured plasma BNP (Shionogi, Osaka) and NT-proBNP (ELECSYS) in 21 healthy individuals (control group [CG]), 11 men, 10 women, mean age 54.4 +/- 11.6 years, with normal ECG and chest X-ray, and in 86 HF patients (HFG), 48 men, 38 women, mean age 71 +/- 11 years, in NYHA II-IV, fulfilling the European Society of Cardiology guidelines: 60 had HF with SD (SDG), ejection fraction (EF) < 40%, and 26 had HF and PSF (PFG), EF > 40%, increased LV mass index and/or dilated left atrium. BNP and NT-proBNP mean and median values were compared and the correlation between the 2 peptides was established. For each peptide sensitivity (sens), specificity (spec) 93.7%, positive predictive value (PPV) 75.5% and negative predictive value (NPV) were calculated. Areas under the ROC curve (AUC) were determined for each group vs. CG and for SDG vs. PFG. Levels of BNP and NT-proBNP were significantly higher in HF patients, particularly in the SDG, than in healthy subjects. There was reasonable agreement between BNP and NT-proBNP. For BNP, AUC were: HFG vs. CG: 97.7-98.0%; SDG vs. CG: 98.6-99.1%; PFG vs. CG: 95.1-95.9%; PFG vs. SDG: 69.7-70.9%; and for NT-proBNP: HFG vs. CG: 99.2-99.3%; SDG vs. CG: 99.6-99.7%; PFG vs. CG: 98.3-98.5%; PFG vs. SDG: 63.3-63.6%. For a cut-off of 32 pg/ml, BNP has 91.7% sens, 93.7% spec, 75.5% PPV and 98.3% NPV. A NT-proBNP cut-off of 126 pg/ml has 96.3% sens, 98.8% spec, 94.3% PPV and 99.3% NPV. Both peptides had an excellent ability to distinguish HF from non-HF subjects. NT-proBNP was more sensitive and specific. Nevertheless, neither peptide could differentiate between the SDG and the PFG by itself. NT-proBNP is a simple, highly effective diagnostic test for HF. A favorable impact on management and costs is expected from implementation of this diagnostic test in clinical practice.


  • Aetiology, Comorbidity and Drug Therapy of Chronic Heart Failure in the Real World: The EPICA Substudy

    by Fátima Ceia, Cândida Fonseca, Teresa Mota, Humberto Morais, Fernando Matias, Catarina Costa, António G. Oliveira

    Background: Chronic heart failure (CHF) is common and is frequently managed by primary care physicians (PCPs). Despite the European Society of Cardiology (ESC) Guidelines, standard treatments for CHF are frequently underutilised, particularly in primary care. Aim: To evaluate current drug therapy for CHF in adults with HF diagnosed according to ESC guidelines in the context of the EPICA study. Aetiological features and therapy relevant comorbidities were also analysed. Methods: EPICA was a community-based epidemiological study conducted in mainland Portugal. The study involved 365 primary care physicians, who evaluated 6300 primary care attendees aged over 25 years. CHF was diagnosed by clinical and echocardiography criteria according to ESC guidelines. Results: Total of 551 cases of CHF were identified, with a mean age of 65±9 years. The estimated overall prevalence of CHF in the Portuguese population was 4.4%; 1.3% with and 1.7% without left ventricular systolic dysfunction (LVSD). There are 6,280,792 people aged >25 years in Portugal, which extrapolates to 261,400 cases of heart failure. About 80% of patients had a history of hypertension, 39% had a history of coronary artery disease and 15% had atrial fibrillation. Only 58% of patients were on angiotensin-converting enzyme (ACE) inhibitors and 7% on beta-blockers. The type of ventricular dysfunction, age and presence of renal failure had little effect on prescription rates. Diuretics were prescribed in 78%. Thiazides were used more frequently in those with preserved systolic function and frusemide in those with left ventricular systolic dysfunction. Digoxin was prescribed more often to patients with than without left ventricular systolic dysfunction (34% vs. 17%; p=0.02). Long-acting nitrates were prescribed to 20% and amiodarone to 8% of patients. Conclusion: The EPICA study, as in other studies in primary care in Europe, particularly the IMPROVEMENT study, suggests that greater efforts are required to improve training of primary care teams in the management of CHF.